Menu

Latest Pharma Insights



Sanofi Celebrates As Venglustat Finally Crosses The Line
The FDA has approved the French firm's GCS inhibitor, which will be marketed as Infilbray and is the first treatment for the neurological symptoms of type 3 Gaucher disease.
Scrip - November 19, 2026
People On The Move: Appointments At Karo, Haleon, Bayer Consumer Health
A round-up of the latest moves in Europe's consumer health sector: Karo Healthcare names CEO; Haleon appoints chief growth officer; Bayer gets new cluster head for Germany and Austria.
HBW Insight - November 19, 2026
How Does Novartis Plan To Grow Through A Second Round Of Patent Expirations?
Novartis growth guidance is 5% a year through 2031, from 5-6% from 2025 to 2030, as Kisqali loses US exclusivity. Peak sales guidance for three drugs rose to $18bn.
Scrip - November 19, 2026
Jefferies Healthcare Conference: Globus Targets Nevro Right-Sizing And Outcomes Improvements
Globus CFO Kyle Kline spoke about strategic plans for 2027 at the Jefferies Healthcare Conference, London, on Nov. 18.
Medtech Insight - November 19, 2026
Why FDA’s Home-Ventilator Product Code Undercounts A Thinning Market
Philips is barred from new US sales, Medtronic and Resmed have made their ventilators obsolete and Vyaire’s ventilator lines now belong to Zoll. There is only one company still winning 510(k) clearances under FDA’s dedicated home-ventilator product code.
Medtech Insight - November 19, 2026
OPPI Seeks RDP, Faster Clinical Trial Reforms To Attract Pharma R&D To India
OPPI is looking to secure policy changes that would encourage global drugmakers to expand their research centres and clinical development programs in India
Scrip - November 19, 2026
Viatris Expects Immediate Boost After Completing Pacira Acquisition
Viatris has completed its acquisition of Pacira BioSciences, pointing to an immediate additional sales contribution of as much as $100m that it expects to bring in by the end of this year.
Generics Bulletin - November 19, 2026
Sandoz Benefits From New Zealand Reliance Pathway To Rapidly Gain Paliperidone Approval
Under New Zealand’s new “rule of two” pathway, Sandoz has received approval for its paliperidone generic in just 25 working days. Regulator Medsafe says the approach saved around 10 months of assessment time and is already in discussions with other firms interested in using the expedited process.
Generics Bulletin - November 19, 2026
Biocon Celebrates Milestone First European Approval Via Streamlined Biosimilar Pathway
Biocon has celebrated the first biosimilar approval under the European Medicines Agency’s new tailored regulatory approach that does not typically require Phase III comparative efficacy studies. The firm’s Pebrilzo pertuzumab rival to Perjeta is set to hit the EU market early next year.
Generics Bulletin - November 19, 2026
Treehill’s Pashazadeh On China, The Funding Drought And Why Biotech’s Model Has To Change
Ali Pashazadeh of Treehill Partners tells In Vivo which of his public predictions on biotech financing, clinical development and China proved right, which didn’t, and what he expects over the next two years.
In Vivo - November 19, 2026
Tanabe Shuts Down NeuroDerm, Along With Approved Parkinson’s Drug
Decision resulted from “a comprehensive review of future strategy” and follows series of other divestment moves by Tanabe since Bain Capital acquisition.
Scrip - November 19, 2026
Machine Learning In Life Sciences: A Blueprint For Regulated AI Adoption
Industry benchmarks indicate that 70% of healthcare and life sciences organizations are actively using AI in 2026, and the adoption of generative AI and large language models (LLMs) has surged, underlining how these technologies have become core strategic imperatives.
In Vivo - November 19, 2026
Novartis Taps Taiwan’s OBI In Potential $2bn+ ADC Platform Alliance
Novartis signs deal to apply Taiwanese antibody-drug conjugate platform specialist's technologies in latest bid to create differentiated assets in crowded space.
Scrip - November 19, 2026
Senate Hemp Regulation Bill Increases THC Level To 1%, But Excludes Common Ingredients
Sens. Amy Klobuchar and Tim Sheehey introduce Hemp Guardrails Act to increase to 1% the limit for any THC in lawful hemp while excluding delta-8 and -10 and other THCs common in products.
HBW Insight - November 19, 2026
Coty’s Langan On Iconic Brands: ‘Protect What’s Timeless,’ Evolve The Rest
Kara Langan, the new head of Coty’s Consumer Beauty US business, shares her views on heritage brands, accessible beauty and what today’s shoppers want.
HBW Insight - November 19, 2026

Sanofi Celebrates As Venglustat Finally Crosses The Line
The FDA has approved the French firm's GCS inhibitor, which will be marketed as Infilbray and is the first treatment for the neurological symptoms of type 3 Gaucher disease.
Scrip - November 19, 2026
How Does Novartis Plan To Grow Through A Second Round Of Patent Expirations?
Novartis growth guidance is 5% a year through 2031, from 5-6% from 2025 to 2030, as Kisqali loses US exclusivity. Peak sales guidance for three drugs rose to $18bn.
Scrip - November 19, 2026
OPPI Seeks RDP, Faster Clinical Trial Reforms To Attract Pharma R&D To India
OPPI is looking to secure policy changes that would encourage global drugmakers to expand their research centres and clinical development programs in India
Scrip - November 19, 2026
Tanabe Shuts Down NeuroDerm, Along With Approved Parkinson’s Drug
Decision resulted from “a comprehensive review of future strategy” and follows series of other divestment moves by Tanabe since Bain Capital acquisition.
Scrip - November 19, 2026
Novartis Taps Taiwan’s OBI In Potential $2bn+ ADC Platform Alliance
Novartis signs deal to apply Taiwanese antibody-drug conjugate platform specialist's technologies in latest bid to create differentiated assets in crowded space.
Scrip - November 19, 2026

Jefferies Healthcare Conference: Globus Targets Nevro Right-Sizing And Outcomes Improvements
Globus CFO Kyle Kline spoke about strategic plans for 2027 at the Jefferies Healthcare Conference, London, on Nov. 18.
Medtech Insight - November 19, 2026
Why FDA’s Home-Ventilator Product Code Undercounts A Thinning Market
Philips is barred from new US sales, Medtronic and Resmed have made their ventilators obsolete and Vyaire’s ventilator lines now belong to Zoll. There is only one company still winning 510(k) clearances under FDA’s dedicated home-ventilator product code.
Medtech Insight - November 19, 2026

People On The Move: Appointments At Karo, Haleon, Bayer Consumer Health
A round-up of the latest moves in Europe's consumer health sector: Karo Healthcare names CEO; Haleon appoints chief growth officer; Bayer gets new cluster head for Germany and Austria.
HBW Insight - November 19, 2026
Senate Hemp Regulation Bill Increases THC Level To 1%, But Excludes Common Ingredients
Sens. Amy Klobuchar and Tim Sheehey introduce Hemp Guardrails Act to increase to 1% the limit for any THC in lawful hemp while excluding delta-8 and -10 and other THCs common in products.
HBW Insight - November 19, 2026
Coty’s Langan On Iconic Brands: ‘Protect What’s Timeless,’ Evolve The Rest
Kara Langan, the new head of Coty’s Consumer Beauty US business, shares her views on heritage brands, accessible beauty and what today’s shoppers want.
HBW Insight - November 19, 2026

Viatris Expects Immediate Boost After Completing Pacira Acquisition
Viatris has completed its acquisition of Pacira BioSciences, pointing to an immediate additional sales contribution of as much as $100m that it expects to bring in by the end of this year.
Generics Bulletin - November 19, 2026
Sandoz Benefits From New Zealand Reliance Pathway To Rapidly Gain Paliperidone Approval
Under New Zealand’s new “rule of two” pathway, Sandoz has received approval for its paliperidone generic in just 25 working days. Regulator Medsafe says the approach saved around 10 months of assessment time and is already in discussions with other firms interested in using the expedited process.
Generics Bulletin - November 19, 2026
Biocon Celebrates Milestone First European Approval Via Streamlined Biosimilar Pathway
Biocon has celebrated the first biosimilar approval under the European Medicines Agency’s new tailored regulatory approach that does not typically require Phase III comparative efficacy studies. The firm’s Pebrilzo pertuzumab rival to Perjeta is set to hit the EU market early next year.
Generics Bulletin - November 19, 2026

Treehill’s Pashazadeh On China, The Funding Drought And Why Biotech’s Model Has To Change
Ali Pashazadeh of Treehill Partners tells In Vivo which of his public predictions on biotech financing, clinical development and China proved right, which didn’t, and what he expects over the next two years.
In Vivo - November 19, 2026
Machine Learning In Life Sciences: A Blueprint For Regulated AI Adoption
Industry benchmarks indicate that 70% of healthcare and life sciences organizations are actively using AI in 2026, and the adoption of generative AI and large language models (LLMs) has surged, underlining how these technologies have become core strategic imperatives.
In Vivo - November 19, 2026